IKTEarnings•globenewswire•
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Sentiment:Negative (30)
Summary
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire